These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29964134)

  • 1. Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein.
    Rodrigues L; Raftopoulos KN; Tandrup Schmidt S; Schneider F; Dietz H; Rades T; Franzyk H; Pedersen AE; Papadakis CM; Christensen D; Winter G; Foged C; Hubert M
    J Control Release; 2018 Sep; 285():12-22. PubMed ID: 29964134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-Self-Assemblies Based on Synthetic Analogues of Mycobacterial Monomycoloyl Glycerol and DDA: Supramolecular Structure and Adjuvant Efficacy.
    Martin-Bertelsen B; Korsholm KS; Roces CB; Nielsen MH; Christensen D; Franzyk H; Yaghmur A; Foged C
    Mol Pharm; 2016 Aug; 13(8):2771-81. PubMed ID: 27377146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.
    Yu H; Karunakaran KP; Jiang X; Shen C; Andersen P; Brunham RC
    Infect Immun; 2012 Apr; 80(4):1510-8. PubMed ID: 22290151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes.
    Igietseme JU; Murdin A
    Infect Immun; 2000 Dec; 68(12):6798-806. PubMed ID: 11083798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo.
    Nordly P; Korsholm KS; Pedersen EA; Khilji TS; Franzyk H; Jorgensen L; Nielsen HM; Agger EM; Foged C
    Eur J Pharm Biopharm; 2011 Jan; 77(1):89-98. PubMed ID: 20940050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge.
    Pal S; Davis HL; Peterson EM; de la Maza LM
    Infect Immun; 2002 Sep; 70(9):4812-7. PubMed ID: 12183524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA.
    Blakney AK; McKay PF; Christensen D; Yus BI; Aldon Y; Follmann F; Shattock RJ
    J Control Release; 2019 Jun; 304():65-74. PubMed ID: 31071377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.
    Dixit S; Singh SR; Yilma AN; Agee RD; Taha M; Dennis VA
    Nanomedicine; 2014 Aug; 10(6):1311-21. PubMed ID: 24602605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.
    Pal S; Theodor I; Peterson EM; de la Maza LM
    Infect Immun; 2001 Oct; 69(10):6240-7. PubMed ID: 11553566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge.
    Pal S; Luke CJ; Barbour AG; Peterson EM; de la Maza LM
    Vaccine; 2003 Mar; 21(13-14):1455-65. PubMed ID: 12615442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.
    Pal S; Peterson EM; de la Maza LM
    Infect Immun; 2005 Dec; 73(12):8153-60. PubMed ID: 16299310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming.
    McEntee CP; Moran HBT; Muñoz-Wolf N; Liddicoat AM; Carroll EC; Erbo-Wern J; Coulter IS; Andersen P; Follmann F; Lavelle EC
    Vaccine; 2020 Jan; 38(3):635-643. PubMed ID: 31727505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa.
    Schautteet K; Stuyven E; Beeckman DS; Van Acker S; Carlon M; Chiers K; Cox E; Vanrompay D
    Vaccine; 2011 Feb; 29(7):1399-407. PubMed ID: 21195805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4
    Schmidt ST; Neustrup MA; Harloff-Helleberg S; Korsholm KS; Rades T; Andersen P; Christensen D; Foged C
    Pharm Res; 2017 Aug; 34(8):1716-1727. PubMed ID: 28516400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
    APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Lipid-Based Hexosomes as Versatile Vaccine Carriers.
    Rodrigues L; Kyriakos K; Schneider F; Dietz H; Winter G; Papadakis CM; Hubert M
    Mol Pharm; 2016 Nov; 13(11):3945-3954. PubMed ID: 27607892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
    Sun G; Pal S; Weiland J; Peterson EM; de la Maza LM
    Vaccine; 2009 Aug; 27(36):5020-5. PubMed ID: 19446590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein-Based Fusion Antigen CTH522 Into Protein Nanoparticles.
    Rose F; Karlsen K; Jensen PR; Jakobsen RU; Wood GK; Rand KD; Godiksen H; Andersen P; Follmann F; Foged C
    J Pharm Sci; 2018 Jun; 107(6):1690-1700. PubMed ID: 29452143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
    Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
    J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.